CDD and AI for Biologics Summit Hotel Commonwealth, Boston

AI/ML and computational use cases for biologics design and optimization are at a critical turning point. Latent Labs’ launch to develop biologics using advanced AI models, Eli Lilly’s TuneLab partnering with BigHat Bio and Chai Discovery, and Bayer’s collaboration with Cradle on AI-enabled antibody discovery, emphasize the role of AI as the key accelerant in re-architecting biologics workflows to expedite discovery to lead candidate optimization.

The re-imagined CDD and AI for Biologics Summit returns at this industry-defining moment to deliver key learnings on applied, experimentally validated use cases to support you in catalyzing biologics discovery innovation. Dive into the convergence of computational drug design and AI applications in de novo protein design, property prediction, multi-objective optimization, molecular dynamics mapping and developability assessment for biologics.